Research Library

Baker Institute director Edward P. Djerejian, former ambassador to Israel and to Syria, appeared on Al-Jazeera's "From Washington" program to discuss the possible consequences of Jamal Khashoggi's disappearance (Arabic): https://youtu.be/J7-xALrG_3s.

While the U.S. still maintains the overall lead in Nobel prizes (with the exception of literature), the rate at which American scientists have been awarded the prize has declined since the late 1970s. Fellow Kirstin R.W. Matthews and postdoctoral fellow Kenneth M. Evans explore the state of scientific collaboration in the U.S. in this Baker Institute blog: https://bit.ly/2yiNhzF

Baker Institute director Edward P. Djerejian comments on a welcome moment of nonpartisanship after the April 21, 2018, funeral for former first lady Barbara Bush. 

High cancer drug prices reduce access to therapy, cause treatment abandonment and financial bankruptcies, as well as severe emotional and family distress.

The 340B Drug Pricing Program, which allows uninsured or low-income patients to buy prescription drugs at discounted prices, is under attack.

In this commentary, the authors examine the roots of the United States’ reluctance to embrace universal health care, concluding that it "is neither sound nor ethical in a nation that promulgates fairness and equal opportunity" to deny coverage.

Contrasting perceptions of the real "winner" of of Iran nuclear deal may have disastrous regional implications.

It is inconceivable to imagine our nation today without the gains of the Civil Rights Act. It is impossible to understand why the issue was so divisive then, since it is such an obvious right and moral proposition. Similarly, let us hope we will look back at the Affordable Care Act 20 years from now and wonder why it was such a contentious topic in 2014.

Cancer drug shortages are almost uniquely associated with generic drugs (small profit margins) and rarely with patented drugs (large profit margins). They are common in the U.S., but uncommon in Europe and elsewhere, where generic drug prices are on average higher than in the U.S. This suggests the main cause of drug shortages is economic.